{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:03:38Z","timestamp":1748491418613,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02653-4","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:02:55Z","timestamp":1748426575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Online adaptive stereotactic body radiotherapy for localized prostate cancer in patients with lower urinary tract symptoms and\/or prostate hyperplasia (X-SMILE)"],"prefix":"10.1186","volume":"20","author":[{"given":"Tiuri","family":"Kroese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiano","family":"Silvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Tanadini-Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Pouymayou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Mencarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Fesslmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Schiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mayinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"1","key":"2653_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin Jan. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin Jan"},{"issue":"10","key":"2653_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw Oct. 2023;21(10):1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw Oct"},{"issue":"9","key":"2653_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Sep. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol Sep"},{"issue":"17","key":"2653_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"27","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year outcomes after monitoring, surgery, or radiotherapy for prostate Cancer. N Engl J Med Apr. 2023;27(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med Apr"},{"issue":"8","key":"2653_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol Aug. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol Aug"},{"issue":"10196","key":"2653_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"3","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet Aug. 2019;3(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet Aug"},{"key":"2653_CR7","doi-asserted-by":"publisher","unstructured":"van As N, Yasar B, Griffin C, et al. Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial. Eur Urol Sep. 2024;11. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.030.","DOI":"10.1016\/j.eururo.2024.08.030"},{"issue":"4","key":"2653_CR8","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1016\/j.ijrobp.2023.08.027","volume":"15","author":"N van As","year":"2023","unstructured":"van As N, Tree A, Patel J, et al. 5-Year outcomes from PACE B: an international phase ill randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. Conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate Cancer. Int J Radiat Oncol Nov. 2023;15(4):E2\u20133.","journal-title":"Int J Radiat Oncol Nov"},{"issue":"7\u20138","key":"2653_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.bulcan.2022.03.011","volume":"109","author":"C Pisani","year":"2022","unstructured":"Pisani C, Galla A, Loi G, Beldi D, Krengli M. Urinary toxicity in patients treated with radical EBRT for prostate cancer: analysis of predictive factors in an historical series. Bull Cancer Jul-Aug. 2022;109(7\u20138):826\u201333. https:\/\/doi.org\/10.1016\/j.bulcan.2022.03.011.","journal-title":"Bull Cancer Jul-Aug"},{"issue":"1","key":"2653_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","volume":"116","author":"N Yahya","year":"2015","unstructured":"Yahya N, Ebert MA, Bulsara M, et al. Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: an analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol Jul. 2015;116(1):112\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2015.06.011.","journal-title":"Radiother Oncol Jul"},{"key":"2653_CR11","doi-asserted-by":"publisher","unstructured":"Ratnakumaran R, Hinder V, Brand D, et al. The association between acute and late genitourinary and Gastrointestinal toxicities: an analysis of the PACE B study. Cancers (Basel). Feb. 2023;17(4). https:\/\/doi.org\/10.3390\/cancers15041288.","DOI":"10.3390\/cancers15041288"},{"issue":"2","key":"2653_CR12","doi-asserted-by":"publisher","first-page":"100805","DOI":"10.1016\/j.adro.2021.100805","volume":"7","author":"D Natesan","year":"2022","unstructured":"Natesan D, Carpenter DJ, Floyd W, et al. Effect of large prostate volume on efficacy and toxicity of moderately hypofractionated radiation therapy in patients with prostate Cancer. Adv Radiat Oncol Mar-Apr. 2022;7(2):100805. https:\/\/doi.org\/10.1016\/j.adro.2021.100805.","journal-title":"Adv Radiat Oncol Mar-Apr"},{"issue":"12","key":"2653_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"20","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med Mar. 2008;20(12):1250\u201361. https:\/\/doi.org\/10.1056\/NEJMoa074311.","journal-title":"N Engl J Med Mar"},{"key":"2653_CR14","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.ctro.2024.100771","volume":"46","author":"CA Fink","year":"2024","unstructured":"Fink CA, Ristau J, Buchele C, et al. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial. Clin Transl Radiat Oncol May. 2024;46:100771. https:\/\/doi.org\/10.1016\/j.ctro.2024.100771.","journal-title":"Clin Transl Radiat Oncol May"},{"issue":"1","key":"2653_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","volume":"1","author":"MJ Zelefsky","year":"2019","unstructured":"Zelefsky MJ, Kollmeier M, McBride S, et al. Five-Year outcomes of a phase 1 Dose-Escalation study using stereotactic body radiosurgery for patients with Low-Risk and Intermediate-Risk prostate Cancer. Int J Radiat Oncol Biol Phys May. 2019;1(1):42\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.045.","journal-title":"Int J Radiat Oncol Biol Phys May"},{"key":"2653_CR16","unstructured":"NRG Oncology. Stereotactic body radiation therapy or Intensity-Modulated radiation therapy in treating patients with stage IIA-B Prostate Cancer. 2017 https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03367702"},{"key":"2653_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol Jun. 2020;147:92\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015.","journal-title":"Radiother Oncol Jun"},{"issue":"2","key":"2653_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","volume":"127","author":"HC Quon","year":"2018","unstructured":"Quon HC, Ong A, Cheung P, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. Radiother Oncol May. 2018;127(2):206\u201312. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.029.","journal-title":"Radiother Oncol May"},{"issue":"1","key":"2653_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11934-024-01229-1","volume":"1","author":"M Elsaqa","year":"2024","unstructured":"Elsaqa M, El Tayeb MM. The role of transurethral BPH surgeries in management of urinary symptoms in prostate Cancer patients, narrative review. Curr Urol Rep Oct. 2024;1(1):7. https:\/\/doi.org\/10.1007\/s11934-024-01229-1.","journal-title":"Curr Urol Rep Oct"},{"issue":"9","key":"2653_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/iju.12460","volume":"21","author":"M Pinkawa","year":"2014","unstructured":"Pinkawa M, Klotz J, Djukic V, Petz D, Holy R, Eble MJ. Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life. Int J Urol Sep. 2014;21(9):899\u2013903. https:\/\/doi.org\/10.1111\/iju.12460.","journal-title":"Int J Urol Sep"},{"key":"2653_CR21","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.ctro.2024.100779","volume":"46","author":"M Galienne","year":"2024","unstructured":"Galienne M, Risbourg S, Lacornerie T, et al. Extreme hypofractionated stereotactic radiotherapy for localized prostate cancer: efficacy and late urinary toxicity according to transurethral resection of the prostate history. Clin Transl Radiat Oncol May. 2024;46:100779. https:\/\/doi.org\/10.1016\/j.ctro.2024.100779.","journal-title":"Clin Transl Radiat Oncol May"},{"issue":"4","key":"2653_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2024.06.003","volume":"15","author":"M Singh","year":"2024","unstructured":"Singh M, Maitre P, Krishnan A, et al. Late urinary toxicity after extreme or moderate hypofractionated prostate radiation therapy in patients with prior transurethral resection of prostate. Int J Radiat Oncol Biol Phys Nov. 2024;15(4):1011\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.003.","journal-title":"Int J Radiat Oncol Biol Phys Nov"},{"key":"2653_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","volume":"149","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Quon H, Ong A, et al. Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol Aug. 2020;149:8\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.039.","journal-title":"Radiother Oncol Aug"},{"key":"2653_CR24","doi-asserted-by":"publisher","first-page":"109713","DOI":"10.1016\/j.radonc.2023.109713","volume":"185","author":"L De Cock","year":"2023","unstructured":"De Cock L, Draulans C, Pos FJ, et al. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol Aug. 2023;185:109713. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713.","journal-title":"Radiother Oncol Aug"},{"key":"2653_CR25","doi-asserted-by":"publisher","unstructured":"Kishan AU, Lamb JM, Wilhalme H, et al. Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial. Eur Urol Nov. 2024;12. https:\/\/doi.org\/10.1016\/j.eururo.2024.10.026.","DOI":"10.1016\/j.eururo.2024.10.026"},{"issue":"3","key":"2653_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"5","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. Feb 2013;5(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"issue":"15","key":"2653_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"17","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate Cancer. N Engl J Med Oct. 2024;17(15):1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med Oct"},{"issue":"3","key":"2653_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/s0360-3016(02)03011-0","volume":"1","author":"L Kestin","year":"2002","unstructured":"Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys Nov. 2002;1(3):686\u201397. https:\/\/doi.org\/10.1016\/s0360-3016(02)03011-0.","journal-title":"Int J Radiat Oncol Biol Phys Nov"},{"issue":"10","key":"2653_CR29","doi-asserted-by":"publisher","first-page":"e2337165","DOI":"10.1001\/jamanetworkopen.2023.37165","volume":"2","author":"SA Qureshy","year":"2023","unstructured":"Qureshy SA, Diven MA, Ma X, et al. Differential use of radiotherapy fractionation regimens in prostate Cancer. JAMA Netw Open Oct. 2023;2(10):e2337165. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.37165.","journal-title":"JAMA Netw Open Oct"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02653-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02653-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:02:56Z","timestamp":1748426576000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02653-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02653-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The final protocol was approved by the Ethics Committee of the University of Zurich, Zurich, Switzerland (Zurich: 2024\u2009\u2212\u200900115). The X-SMILE study complies with the Helsinki Declaration in its recent German version, the principles of Good Clinical Practice (GCP) and the General Data Protection Regulation (GDPR) as well as the Federal Data Protection Act (FDPA). The trial will also be carried out in accordance with local legal and regulatory requirements. The ClinicalTrials.gov identifier is NCT06834152.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Substantial changes to the project set-up, the protocol and relevant project documents will be submitted to the Ethics Committee for approval according to HRO Art. 18 before implementation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol amendments"}},{"value":"The sponsor had a role in the study design, but not in the collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. The funder had no role in the study design, collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Roles and responsibilities"}},{"value":"Project data will be handled with uttermost discretion and is only accessible to authorized personnel who require the data to fulfil their duties within the scope of the research project. On the CRFs and other project specific documents, participants are only identified by a unique participant number. The project site personnel maintain a participant identification list, in which the participant identification numbers are linked to the full participant names and dates of birth. This list will be kept strictly confidential and must not leave the project site. After completion of the project, the participant identification list will be archived for 15 years. All clinical data entered into the database, including electronic case report forms (eCRFs), radiation treatment plans and imaging data, will only be transmitted in pseudonymized form.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Confidentiality"}},{"value":"The insurance costs will be covered by the sponsor. Local insurance will be arranged in accordance with local regulations, where applicable. Policy Number: 14.970.888.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ancillary and post-trial care"}},{"value":"Responsibility for the publication of the results lies with the project management. Until this time, all information on the research project must be treated confidentially. The final publication is planned for after the end of the project. All participating centers will be included in the publication, either as named authors or to the extent that the number of possible co-authors allows. Authors agree to make data and materials supporting the results or analyses presented in their paper available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dissemination policy"}},{"value":"J.L. declares Speaker fee from Accuary and Traveling costs from Micropos Medical and from RaySearch Laboratories. The remaining authors declare no conflict of interest.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}